AbbVie: FDA To Review BLA For Epcoritamab
COPENHAGEN (dpa-AFX) - AbbVie (ABBV) announced the FDA has accepted for priority review the Biologics License Application for epcoritamab, an…
192,940$
-0,26%
Echtzeit-Aktienkurs ABBVIE
Bid:
Ask:
Nachrichten zur ABBVIE Aktie
AbbVie, Genmab Get FDA Priority Review of Epcoritamab in Large B-Cell Lymphoma
AbbVie, Genmab Get FDA Priority Review of Epcoritamab in Large B-Cell Lymphoma...…
Meta, AbbVie among new names in UBS 2023 stock focus list
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Where AbbVie Stands With Analysts
Latest Ratings for ABBV
DateFirmActionFromTo Feb 2022UBSDowngradesBuyNeutral Feb 2022MizuhoMaintainsBuy Feb 2022BarclaysMaintainsEqual-Weight
View More Analyst Ratings…
AMCP Foundation Interns Delve into Oncology, Evidence Gaps, Medication Adherence in Partnership with AbbVie Inc. and Pfizer Inc.
ALEXANDRIA, Va., Nov. 17, 2022 /PRNewswire/ -- AMCP Foundation congratulates the student pharmacists who recently completed immersive managed care centered…
Fourth Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day Most Successful One Yet
A RECORD-BREAKING NUMBER OF CONSUMERS PARTICIPATED, WITH BOGO GIFT CARDS SELLING OUT IN JUST A FEW HOURS11 IRVINE, Calif., Nov.…
AbbVie Presents Data from Extensive Portfolio at the American College of Rheumatology Convergence 2022
Thirty-six abstracts underscore AbbVies commitment to advancing research to help more people living with rheumatic diseases Additional analysis of long-term…
AbbVie downgraded to hold at Societe Generale on weakness in blood cancer, aesthetics
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
AbbVie: Phase 2 Trial Of AGN-151607 In POAF In Cardiac Surgery Patients Fails To Meet Main Goal
WASHINGTON (dpa-AFX) - AbbVie (ABBV) announced results from its exploratory NOVA phase 2 dose-ranging study evaluating the efficacy and safety…
AbbVie candidate for postoperative atrial fibrillation fails in mid-stage trial
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
3 Reasons to Buy AbbVie Stock Right Now
The drugmaker has something to offer to all kinds of investors....…
Form 10-Q AbbVie Inc. For: Sep 30
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Better Buy: AbbVie vs. Walgreens Boots Alliance
Both these companies pay a dividend, but the similarities stop there....…
REGENXBIO Reports Third Quarter 2022 Financial Results and Recent Operational Highlights
Continued progress on 5x25 strategy to advance five AAV Therapeutics from our internal pipeline and licensed programs into pivotal-stage or…
Why Dividend Investors Can Still Buy AbbVie Stock With No Worries
The big-pharma companys dividend remains safe and sound....…
6 Stocks With Healthy Dividends and Solid Returns
AbbVie, Gilead Sciences, Cardinal Health, Merck, Bristol Myers, and Amgen are large-cap healthcare companies that have the capacity to grow…
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could…
Exxon Mobil, AbbVie, and Visa Raised Dividends
Energy giant Exxon Mobil, pharmaceutical firm AbbVie, and cards firm Visa were among the U.S. companies that announced dividend increases…
Inventiva stock dips as AbbVie abandons cedirogant program for autoimmune disease
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
AbbVie (ABBV) Q3 2022 Earnings Call Transcript
ABBV earnings call for the period ending September 30, 2022....…
Three buys and a bail: AbbVie, Eli Lilly, Humana and Moderna
Gina Sanchez, Lido Advisors chief market strategist, joins 'The Exchange' to discuss three stocks Sanchez is interested in buying and…
AbbVie Says EMA Validates MAA For Epcoritamab To Treat Relapsed/refractory Diffuse Large B-cell
WASHINGTON (dpa-AFX) - AbbVie (ABBV) announced Friday that the European Medicines Agency (EMA) has validated a Marketing Authorization Application (MAA)…
Genmab files for approval of blood cancer drug in US, AbbVie gets review in EU
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
AbbVie Reports Mixed Earnings, Tightens Guidance, Lifts Quarterly Dividend
read more...…
AbbVie Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Large B-Cell Lymphoma (LBCL)
European Medicines Agency (EMA) validates AbbVies Marketing Authorization Application; Genmab submits Biologics License Application to U.S. Food and Drug Administration…
ROUNDUP: AbbVie Q3 Profit Up, Beats Estimates; Narrows Full-year Earnings Outlook
WASHINGTON (dpa-AFX) - (Adds Outlook, Dividend)AbbVie (ABBV) released earnings for its third quarter that increased from last year and beat…
AbbVie Q3 Profit Increases, beats estimates
WASHINGTON (dpa-AFX) - AbbVie (ABBV) released earnings for its third quarter that increased from last year and beat the Street…
AbbVie narrows guidance for 2022
Shares of AbbVie Inc. fell 2.9% in premarket trading on Friday after the company trimmed guidance for adjusted earnings…
AbbVie Boosts Quarterly Dividend by 5%
AbbVie Boosts Quarterly Dividend by 5%...…
AbbVie Reports Third-Quarter 2022 Financial Results
Reports Third-Quarter Diluted EPS of $2.21 on a GAAP Basis, an Increase of 24.2 Percent; Adjusted Diluted EPS of $3.66,…
Form 8-K AbbVie Inc. For: Oct 28
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
AbbVie raises dividend by 5% to $1.48
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
AbbVie misses sales estimates as Botox, Juvederm face slowdown jitters
...(Reuters) - AbbVie Inc on Friday missed Wall Street estimates......…
AbbVie Non-GAAP EPS of $3.66 beats by $0.10, revenue of $14.81B misses by $130M, raises dividend by 5%
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
AbbVie Q3 Preview: Can Shares Continue Their Run?
AbbVie shares have been a bright spot in a dim market year-to-date, up a double-digit 17% and easily crushing the…
All eyes on AbbVie Q3 results amid biosimilar competition to rheumatoid arthritis drug Humira
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Insights into the Rheumatoid Arthritis (RA) Online Space, 2022 Report Featuring UCB, Galapagos, BMS, Amgen, Pfizer, Sanofi, AbbVie, Genentech, Janssen, & Eli Lilly
DUBLIN, Oct. 26, 2022 /PRNewswire/ -- The "Rheumatoid Arthritis (RA) Therapy Area Report" report has been added to ResearchAndMarkets.coms offering.…
Übernahme von Botox-Hersteller gibt AbbVie Schub
Frankfurt (Reuters) - Der US-Pharmakonzern AbbVie profitiert von einer hohen Nachfrage nach seinem Blockbuster-Medikament Humira und der Übernahme des Botox-Herstellers…
Agentur - Boehringer und AbbVie in Gesprächen über Krebs-Allianz
Bangalore (Reuters) - Deutschlands zweitgrößter Pharmakonzern Boehringer Ingelheim steht einem Agenturbericht zufolge vor einer umfassenden Partnerschaft bei Krebs-Therapien mit dem…